Legacy Wealth Asset Management LLC Boosts Holdings in Hologic, Inc. (NASDAQ:HOLX)

Legacy Wealth Asset Management LLC increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 16.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,650 shares of the medical equipment provider’s stock after buying an additional 526 shares during the quarter. Legacy Wealth Asset Management LLC’s holdings in Hologic were worth $285,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in Hologic during the 4th quarter valued at about $217,529,000. Pinebridge Investments L.P. boosted its stake in shares of Hologic by 39.8% in the fourth quarter. Pinebridge Investments L.P. now owns 397,251 shares of the medical equipment provider’s stock valued at $28,384,000 after purchasing an additional 113,050 shares during the period. Louisiana State Employees Retirement System acquired a new position in shares of Hologic in the fourth quarter valued at approximately $1,057,000. Thematics Asset Management increased its stake in Hologic by 18.0% during the 4th quarter. Thematics Asset Management now owns 433,487 shares of the medical equipment provider’s stock worth $30,973,000 after buying an additional 66,158 shares during the period. Finally, Cibc World Markets Corp lifted its holdings in Hologic by 133.2% during the 4th quarter. Cibc World Markets Corp now owns 31,524 shares of the medical equipment provider’s stock worth $2,252,000 after buying an additional 18,005 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have commented on HOLX. Stephens assumed coverage on shares of Hologic in a research report on Thursday, June 27th. They issued an “overweight” rating and a $87.00 price objective on the stock. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Evercore ISI cut their target price on Hologic from $78.00 to $76.00 and set an “in-line” rating on the stock in a research report on Tuesday. JPMorgan Chase & Co. upped their price target on Hologic from $85.00 to $91.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. Finally, StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Hologic has an average rating of “Moderate Buy” and a consensus target price of $85.55.

Hologic Price Performance

HOLX traded down $0.05 during midday trading on Thursday, reaching $73.48. 1,201,107 shares of the company’s stock were exchanged, compared to its average volume of 1,344,492. The business’s 50-day moving average price is $74.14 and its 200 day moving average price is $74.36. The stock has a market capitalization of $17.15 billion, a PE ratio of 37.49, a P/E/G ratio of 2.45 and a beta of 0.99. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $82.45. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.97 and a quick ratio of 3.29.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the business earned $1.06 earnings per share. The business’s revenue was down .8% on a year-over-year basis. As a group, equities analysts anticipate that Hologic, Inc. will post 4.08 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.